(IDYA) Ideaya Biosciences - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US45166A1025
Stock: Oncology Therapeutics, Drug Discovery, Clinical Trials
Total Rating 35
Risk 37
Buy Signal -0.44
| Risk 5d forecast | |
|---|---|
| Volatility | 48.2% |
| Relative Tail Risk | -0.70% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.26 |
| Alpha | 58.43 |
| Character TTM | |
|---|---|
| Beta | 0.973 |
| Beta Downside | 0.681 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.23% |
| CAGR/Max DD | 0.44 |
EPS (Earnings per Share)
Revenue
Description: IDYA Ideaya Biosciences March 05, 2026
IDEAYA Biosciences, Inc. (IDYA) is a biotechnology company focused on oncology. It develops targeted therapeutics for cancer patients using molecular diagnostics.
The companys pipeline includes Darovasertib, a PKC inhibitor for uveal melanoma, and IDE849, a DLL3 antibody-drug conjugate for small cell lung cancer (SCLC) and neuroendocrine carcinomas. The oncology sector is characterized by high research and development costs and lengthy clinical trial processes.
IDYA also has several other drug candidates in various clinical phases, including inhibitors for PARG, Pol Theta Helicase, MAT2A, PRMT5, KAT6/7, and Werner protein. Their business model involves strategic alliances with larger pharmaceutical companies to support drug development and commercialization.
Further research on ValueRay can provide detailed insights into IDYAs pipeline and market position.
Headlines to watch out for
- Darovasertib clinical trial success drives stock performance
- IDE849 development progress impacts future revenue
- Strategic alliances with GSK and Pfizer boost pipeline value
- Regulatory approval of new drugs unlocks market potential
- Early-stage pipeline advancements signal long-term growth
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -113.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.07 > 0.02 and ΔFCF/TA 15.75 > 1.0 |
| NWC/Revenue: 278.0% < 20% (prev 9.19k%; Δ -8.92k% < -1%) |
| CFO/TA -0.06 > 3% & CFO -71.1m > Net Income -113.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.6m) vs 12m ago 1.42% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 19.59% > 50% (prev 0.62%; Δ 18.96% > 0%) |
| Interest Coverage Ratio: -11.06 > 6 (EBITDA TTM -120.4m / Interest Expense TTM -11.3m) |
Altman Z'' -8.25
| A: 0.55 (Total Current Assets 666.7m - Total Current Liabilities 58.8m) / Total Assets 1.11b |
| B: -0.66 (Retained Earnings -736.5m / Total Assets 1.11b) |
| C: -0.11 (EBIT TTM -125.0m / Avg Total Assets 1.12b) |
| D: -8.50 (Book Value of Equity -734.3m / Total Liabilities 86.4m) |
| Altman-Z'' Score: -8.25 = D |
Beneish M 1.00
| DSRI: 63.72 (Receivables 5.97m/3.00k, Revenue 218.7m/7.00m) |
| GMI: 0.46 (GM 97.90% / 45.23%) |
| AQI: 1.02 (AQ_t 0.37 / AQ_t-1 0.36) |
| SGI: 31.24 (Revenue 218.7m / 7.00m) |
| TATA: -0.04 (NI -113.7m - CFO -71.1m) / TA 1.11b) |
| Beneish M-Score: 69.77 (Cap -4..+1) = D |
What is the price of IDYA shares?
As of March 16, 2026, the stock is trading at USD 33.09 with a total of 812,928 shares traded.
Over the past week, the price has changed by -5.67%, over one month by +7.57%, over three months by -0.84% and over the past year by +72.97%.
Over the past week, the price has changed by -5.67%, over one month by +7.57%, over three months by -0.84% and over the past year by +72.97%.
Is IDYA a buy, sell or hold?
Ideaya Biosciences has received a consensus analysts rating of 4.69.
Therefore, it is recommended to buy IDYA.
- StrongBuy: 10
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IDYA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 50.1 | 51.3% |
| Analysts Target Price | 50.1 | 51.3% |
IDYA Fundamental Data Overview March 15, 2026
P/E Forward = 4.649
P/S = 13.2859
P/B = 2.8406
Revenue TTM = 218.7m USD
EBIT TTM = -125.0m USD
EBITDA TTM = -120.4m USD
Long Term Debt = 27.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 339k USD (from shortTermDebt, last quarter)
Debt = 55.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -57.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.32b USD (2.91b + Debt 55.5m - CCE 639.4m)
Interest Coverage Ratio = -11.06 (Ebit TTM -125.0m / Interest Expense TTM -11.3m)
EV/FCF = -31.60x (Enterprise Value 2.32b / FCF TTM -73.5m)
FCF Yield = -3.16% (FCF TTM -73.5m / Enterprise Value 2.32b)
FCF Margin = -33.59% (FCF TTM -73.5m / Revenue TTM 218.7m)
Net Margin = -51.99% (Net Income TTM -113.7m / Revenue TTM 218.7m)
Gross Margin = unknown ((Revenue TTM 218.7m - Cost of Revenue TTM 4.59m) / Revenue TTM)
Tobins Q-Ratio = 2.09 (Enterprise Value 2.32b / Total Assets 1.11b)
Interest Expense / Debt = 45.17% (Interest Expense 25.1m / Debt 55.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -98.7m (EBIT -125.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.34 (Total Current Assets 666.7m / Total Current Liabilities 58.8m)
Debt / Equity = 0.05 (Debt 55.5m / totalStockholderEquity, last quarter 1.02b)
Debt / EBITDA = 0.48 (negative EBITDA) (Net Debt -57.3m / EBITDA -120.4m)
Debt / FCF = 0.78 (negative FCF - burning cash) (Net Debt -57.3m / FCF TTM -73.5m)
Total Stockholder Equity = 1.02b (last 4 quarters mean from totalStockholderEquity)
RoA = -10.18% (Net Income -113.7m / Total Assets 1.11b)
RoE = -11.10% (Net Income TTM -113.7m / Total Stockholder Equity 1.02b)
RoCE = -11.87% (EBIT -125.0m / Capital Employed (Equity 1.02b + L.T.Debt 27.9m))
RoIC = -9.64% (negative operating profit) (NOPAT -98.7m / Invested Capital 1.02b)
WACC = 9.99% (E(2.91b)/V(2.96b) * Re(9.50%) + D(55.5m)/V(2.96b) * Rd(45.17%) * (1-Tc(0.21)))
Discount Rate = 9.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 23.18%
[DCF] Fair Price = unknown (Cash Flow -73.5m)
EPS Correlation: -5.12 | EPS CAGR: -16.41% | SUE: -0.00 | # QB: 0
Revenue Correlation: -15.92 | Revenue CAGR: -1.15% | SUE: 0.03 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.99 | Chg7d=+0.001 | Chg30d=-0.066 | Revisions Net=-5 | Analysts=14
EPS current Year (2026-12-31): EPS=-3.93 | Chg7d=-0.002 | Chg30d=-0.373 | Revisions Net=-14 | Growth EPS=-207.4% | Growth Revenue=-82.7%
EPS next Year (2027-12-31): EPS=-3.37 | Chg7d=-0.044 | Chg30d=-0.313 | Revisions Net=-5 | Growth EPS=+14.2% | Growth Revenue=+218.9%
[Analyst] Revisions Ratio: -1.00 (0 Up / 5 Down within 30d for Next Quarter)
P/S = 13.2859
P/B = 2.8406
Revenue TTM = 218.7m USD
EBIT TTM = -125.0m USD
EBITDA TTM = -120.4m USD
Long Term Debt = 27.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 339k USD (from shortTermDebt, last quarter)
Debt = 55.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -57.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.32b USD (2.91b + Debt 55.5m - CCE 639.4m)
Interest Coverage Ratio = -11.06 (Ebit TTM -125.0m / Interest Expense TTM -11.3m)
EV/FCF = -31.60x (Enterprise Value 2.32b / FCF TTM -73.5m)
FCF Yield = -3.16% (FCF TTM -73.5m / Enterprise Value 2.32b)
FCF Margin = -33.59% (FCF TTM -73.5m / Revenue TTM 218.7m)
Net Margin = -51.99% (Net Income TTM -113.7m / Revenue TTM 218.7m)
Gross Margin = unknown ((Revenue TTM 218.7m - Cost of Revenue TTM 4.59m) / Revenue TTM)
Tobins Q-Ratio = 2.09 (Enterprise Value 2.32b / Total Assets 1.11b)
Interest Expense / Debt = 45.17% (Interest Expense 25.1m / Debt 55.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -98.7m (EBIT -125.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.34 (Total Current Assets 666.7m / Total Current Liabilities 58.8m)
Debt / Equity = 0.05 (Debt 55.5m / totalStockholderEquity, last quarter 1.02b)
Debt / EBITDA = 0.48 (negative EBITDA) (Net Debt -57.3m / EBITDA -120.4m)
Debt / FCF = 0.78 (negative FCF - burning cash) (Net Debt -57.3m / FCF TTM -73.5m)
Total Stockholder Equity = 1.02b (last 4 quarters mean from totalStockholderEquity)
RoA = -10.18% (Net Income -113.7m / Total Assets 1.11b)
RoE = -11.10% (Net Income TTM -113.7m / Total Stockholder Equity 1.02b)
RoCE = -11.87% (EBIT -125.0m / Capital Employed (Equity 1.02b + L.T.Debt 27.9m))
RoIC = -9.64% (negative operating profit) (NOPAT -98.7m / Invested Capital 1.02b)
WACC = 9.99% (E(2.91b)/V(2.96b) * Re(9.50%) + D(55.5m)/V(2.96b) * Rd(45.17%) * (1-Tc(0.21)))
Discount Rate = 9.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 23.18%
[DCF] Fair Price = unknown (Cash Flow -73.5m)
EPS Correlation: -5.12 | EPS CAGR: -16.41% | SUE: -0.00 | # QB: 0
Revenue Correlation: -15.92 | Revenue CAGR: -1.15% | SUE: 0.03 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.99 | Chg7d=+0.001 | Chg30d=-0.066 | Revisions Net=-5 | Analysts=14
EPS current Year (2026-12-31): EPS=-3.93 | Chg7d=-0.002 | Chg30d=-0.373 | Revisions Net=-14 | Growth EPS=-207.4% | Growth Revenue=-82.7%
EPS next Year (2027-12-31): EPS=-3.37 | Chg7d=-0.044 | Chg30d=-0.313 | Revisions Net=-5 | Growth EPS=+14.2% | Growth Revenue=+218.9%
[Analyst] Revisions Ratio: -1.00 (0 Up / 5 Down within 30d for Next Quarter)